Lantern Pharma Inc. (Nasdaq: LTRN)

Lantern Pharma Inc. (Nasdaq: LTRN) announced a successful FDA Type C outcome supporting the next phase of development for LP-300 in never-smoker NSCLC. The FDA raised no objections to key proposed amendments to the Phase 2 HARMONIC™ trial, including: 📍 Focused enrollment in EGFR exon 21 L858R patients 📍 Extended LP-300 dosing from 6 → 8 cycles 📍 Transition to a focused single-arm study design These updates are designed to sharpen the clinical signal and advance LP-300 in a high-need molecularly defined patient population. 👉 Swipe through for key highlights and emerging clinical observations from HARMONIC™. 🔗 Read the full release here:https://bit.ly/49FsM2y 🎥 Join our upcoming webinar: https://bit.ly/3RasI4G 🔗 Visit harmonictrial.com to learn more about the trial

🫁 Join us TOMORROW at 3:00 PM ET for a KOL webinar focused on never-smoker NSCLC and the evolving HARMONIC™ clinical trial with new updates following a successful FDA Type C meeting. Rodman & Renshaw will host a fireside chat with Joseph Treat, M.D. of Fox Chase Cancer Center - moderated by Michael G King Jr, Senior Biotechnology Analyst at Rodman & Renshaw, discussing LP-300, the HARMONIC™ trial, and the treatment landscape for never-smoker lung cancer. The discussion follows Lantern Pharma Inc. (Nasdaq: LTRN) ’s recent FDA Type C outcome supporting key amendments to the Phase 2 HARMONIC™ trial, including focused enrollment in EGFR exon 21 L858R patients and an expanded dosing strategy. 📅 Thursday, May 21, 2026 🕒 3:00 PM ET 🔗 Register now: https://lnkd.in/e952-ktA 🔗 Read the recent announcement: https://bit.ly/49FsM2y

🧠 May is Brain Tumor Awareness Month (#GrayMay). Throughout the month, Lantern Pharma Inc. (Nasdaq: LTRN) and our wholly owned subsidiary, Starlight Therapeutics will be sharing facts, insights, and ongoing efforts aimed at raising awareness around brain tumors and the urgent need for better treatment options. An estimated 1 million people in the U.S. are living with a primary brain tumor, while the five-year survival rate for malignant brain cancer remains only 35.7%. At Lantern and Starlight, we remain committed to advancing AI-driven precision oncology approaches for patients facing difficult-to-treat CNS cancers, including glioblastoma and rare pediatric brain tumors. Join us in helping spread awareness this month!

🧬 We’re #hiring at Lantern Pharma! As we continue expanding our AI-driven oncology platform and advancing technologies like withZeta.ai, we’re looking for exceptional scientists and engineers to help shape the future of precision cancer drug development. We are currently hiring for multiple roles across AI, computational biology, software engineering, and platform development, including: 📍 Frontend Engineer — AI Drug Discovery Platform 📍 Biopharma Software Engineer 📍 AI Drug Discovery Scientist 📍 Computational Drug Development Scientist At Lantern, you’ll work at the intersection of: AI & machine learning, Oncology drug discovery, Real-world clinical development, Computational biology & molecular design …and contribute directly to technologies and therapeutic programs designed to accelerate precision oncology. Explore openings and apply: 🌐 https://lnkd.in/e8rAWNaB

Lantern Pharma is excited to announce that Sandra Sinclair, BSBA, MHA/ED, RN, Executive Director of Clinical Operations, will be joining the panel discussion at Fierce Biotech Week 2026 in Boston. Sandra will participate in: “Owning the Inspection Narrative: Traceability, Transparency & Executive Accountability in 2026” The discussion will explore evolving expectations around clinical operations, inspection readiness, transparency, and operational accountability across the biotech industry. 📍 Encore Boston Harbor 📅 May 12, 2026 ⏰ 1:30 PM – 2:15 PM ET We look forward to contributing to the conversation alongside leaders across the biotech and clinical development community. Fierce Biotech Fierce Life Sciences Events

🔴Lantern Pharma Inc. (Nasdaq: LTRN) unveils the next development roadmap for withZeta.ai — introducing ZetaSwarm™, ZetaOmics™. Today, we announced the next phase in the evolution of withZeta.ai, our multi-agentic AI co-scientist platform for oncology research and drug discovery. The roadmap introduces three major capability tracks: 📍 ZetaSwarm™ — autonomous multi-agent swarm intelligence designed for parallel scientific reasoning across complex research problems 📍 ZetaOmics™ — a real-time computational biology and multi-omic analytics toolkit enabling deep biomarker and drug-response analysis directly within the research workflow 📍 Enterprise-grade platform capabilities — including organizational workspaces, private knowledge bases, audit trails, and institutional deployment infrastructure Together, these planned capabilities are designed to move withZeta.ai beyond literature synthesis alone — toward coordinated scientific reasoning, real computational analysis, and AI-native oncology research workflows. We believe this roadmap represents an important step toward the next generation of AI-enabled biomedical research infrastructure. 🔗 Learn more: https://withzeta.ai 🔗 Read the full announcement: https://bit.ly/4weTdpt

Lantern Pharma CEO & President Panna Sharma to Participate in Polsinelli’s 2026 Healthcare Dealmakers Conference! Lantern Pharma Inc. (Nasdaq: LTRN) will participate in the upcoming 2026 Healthcare Dealmakers Conference in Dallas, TX(May 13–14), where our President & CEO, Panna Sharma, will discuss the role of AI in transforming oncology drug discovery and development. The conference brings together healthcare leaders, innovators, and capital partners to explore the evolving landscape of dealmaking and strategic collaboration across the sector. We look forward to engaging with the broader healthcare and investment community. Learn more: healthcaredealmakers.com #2026HDC

🧬 From prediction → to real-time molecular intelligence. Lantern Pharma Inc. (Nasdaq: LTRN) have evolved predictBBB.ai into a Large Quantitative Model (LQM) — a new class of AI designed to compute the quantitative language of chemistry in real time. With a single SMILES string, researchers can now generate a 360° molecular developability profile in seconds — spanning physicochemical properties, drug-likeness, structural architecture, and topology. What previously required multiple tools, fragmented workflows, and hours of analysis can now be done instantly, in one unified interface. This is not a language model approximating science — it’s a quantitative engine calculating molecular behavior directly, now fully integrated into withZeta.ai and accessible to researchers globally. 🔗 read the full release : https://bit.ly/4tGcVc7 🔗 visit withzeta.ai: https://withzeta.ai

“The rarest cancers have always faced the longest waits — not because the science is absent, but because the infrastructure to move at the speed of urgency has never existed.” In a recent statement, our CEO Panna Sharma shared a perspective that continues to shape our approach to drug discovery — and why we built withZeta.ai. “withZeta.ai is not a search engine, not a literature tool, and not a chatbot with oncology data loaded in. It is a multi-agentic AI-powered co-scientist… capable of executing research workflows and drug development decision making in real time — things that would otherwise take months or longer.” On April 30th, we are inviting the world to see it operate — live, unrehearsed, and without restriction. 📅 Join us live on April 30, 2026 to see withZeta.ai in action: Morning Session — 8:30 AM ET 🔗 Register: https://lnkd.in/eDFgnKvA Afternoon Session — 4:30 PM ET 🔗 Register: https://lnkd.in/eC2rA-8M 🚀 withZeta.ai is now live and open for subscription 🔗 https://withzeta.ai/ #AIinbiotech #precisiononcology #drugdiscovery #LTRN

Thank you to everyone who stopped by at AACR Annual Meeting 2026 — we had an incredible time connecting with researchers, clinicians, and partners from across the global oncology community. From live demos of withZeta.ai to deep scientific discussions, the level of engagement and curiosity around AI-driven drug discovery was energizing to see. Now that AACR has wrapped, we’re carrying that momentum forward. 🚀 withZeta.ai is now live and open for subscription — bringing multi-agent AI workflows into real-world drug discovery, development, and clinical strategy. If you didn’t get a chance to see withZeta.ai in action in San Diego, we’d love to connect: 📍 Request a virtual demo: contact@withzeta.ai 🔗 Explore the platform: https://withzeta.ai Looking forward to continuing the conversations ahead. #AACR2026